Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Susan Bal; Ehsan Malek; Ankit Kansagra; Saad Z. Usmani; Ravi Vij; Kelly N. Godby; Robert F. Cornell; Yubin Kang; Elvira Umyarova; Smith Giri; Saurabh Chhabra; Michaela Liedtke; Natalie S. Callander; Parameswaran Hari; Shaji Kumar; Luciano J. Costa

doi:10.1038/s41375-021-01471-3

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Susan Bal, Ehsan Malek, Ankit Kansagra, Saad Z. Usmani, Ravi Vij, Kelly N. Godby, Robert F. Cornell, Yubin Kang, Elvira Umyarova, Smith Giri, Saurabh Chhabra, Michaela Liedtke, Natalie S. Callander, Parameswaran Hari, Shaji Kumar, Luciano J. Costa

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Journal	Leukemia
DOIs	https://doi.org/10.1038/s41375-021-01471-3
State	Accepted/In press - 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01471-3

Cite this

Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., Cornell, R. F., Kang, Y., Umyarova, E., Giri, S., Chhabra, S., Liedtke, M., Callander, N. S., Hari, P., Kumar, S., & Costa, L. J. (Accepted/In press). Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. https://doi.org/10.1038/s41375-021-01471-3

@article{25e60aa52e224ea28e43b3dc0eb8843c,

title = "Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies",

author = "Susan Bal and Ehsan Malek and Ankit Kansagra and Usmani, {Saad Z.} and Ravi Vij and Godby, {Kelly N.} and Cornell, {Robert F.} and Yubin Kang and Elvira Umyarova and Smith Giri and Saurabh Chhabra and Michaela Liedtke and Callander, {Natalie S.} and Parameswaran Hari and Shaji Kumar and Costa, {Luciano J.}",

note = "Funding Information: EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity{\textquoteright}s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity{\textquoteright}s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). SB has received research funding from Amyloid Foundation. SG is supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and reports receiving research funding from Carevive Systems and Pack Health. SC: Research Funding: Amgen, Janssen, Sanofi; Honorarium: Glaxo Smith Kline. Other authors do not have any conflicts of interest to disclose.",

year = "2021",

doi = "10.1038/s41375-021-01471-3",

language = "English (US)",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Treatment outcomes of triple class refractory multiple myeloma

T2 - a benchmark for new therapies

AU - Bal, Susan

AU - Malek, Ehsan

AU - Kansagra, Ankit

AU - Usmani, Saad Z.

AU - Vij, Ravi

AU - Godby, Kelly N.

AU - Cornell, Robert F.

AU - Kang, Yubin

AU - Umyarova, Elvira

AU - Giri, Smith

AU - Chhabra, Saurabh

AU - Liedtke, Michaela

AU - Callander, Natalie S.

AU - Hari, Parameswaran

AU - Kumar, Shaji

AU - Costa, Luciano J.

N1 - Funding Information: EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity’s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity’s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). SB has received research funding from Amyloid Foundation. SG is supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and reports receiving research funding from Carevive Systems and Pack Health. SC: Research Funding: Amgen, Janssen, Sanofi; Honorarium: Glaxo Smith Kline. Other authors do not have any conflicts of interest to disclose.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85119448679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119448679&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01471-3

DO - 10.1038/s41375-021-01471-3

M3 - Article

C2 - 34802043

AN - SCOPUS:85119448679

SN - 0887-6924

JO - Leukemia

JF - Leukemia

ER -

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this